CMG Pharmaceutical Co. Ltd (KQ:058820) — Market Cap & Net Worth
Market Cap & Net Worth: CMG Pharmaceutical Co. Ltd (058820)
CMG Pharmaceutical Co. Ltd (KQ:058820) has a market capitalization of $107.20 Million (₩158.19 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19015 globally and #909 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CMG Pharmaceutical Co. Ltd's stock price ₩1070.00 by its total outstanding shares 147842183 (147.84 Million). Review total liabilities of CMG Pharmaceutical Co. Ltd to assess the company's total debt and financial obligations.
CMG Pharmaceutical Co. Ltd Market Cap History: 2015 to 2026
CMG Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $183.09 Million to $107.20 Million (-6.73% CAGR).
Index Memberships
CMG Pharmaceutical Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.04% | #366 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.04% | #366 of 1384 |
Weight: CMG Pharmaceutical Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CMG Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CMG Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
CMG Pharmaceutical Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $296.79 Million | $32.97 Billion | $1.73 Billion | 0.01x | 0.17x |
| 2017 | $582.39 Million | $41.54 Billion | $2.83 Billion | 0.01x | 0.21x |
| 2018 | $395.26 Million | $49.86 Billion | $6.07 Billion | 0.01x | 0.07x |
| 2019 | $425.81 Million | $58.62 Billion | $3.05 Billion | 0.01x | 0.14x |
| 2020 | $579.10 Million | $64.46 Billion | $215.00 Million | 0.01x | 2.69x |
| 2021 | $384.23 Million | $69.48 Billion | $3.17 Billion | 0.01x | 0.12x |
| 2022 | $215.41 Million | $82.20 Billion | -$388.14 Million | 0.00x | N/A |
| 2023 | $241.46 Million | $93.91 Billion | $6.46 Billion | 0.00x | 0.04x |
| 2024 | $177.14 Million | $99.10 Billion | $2.69 Billion | 0.00x | 0.07x |
| 2025 | $186.15 Million | $105.23 Billion | -$10.08 Billion | 0.00x | N/A |
Competitor Companies of 058820 by Market Capitalization
Companies near CMG Pharmaceutical Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to CMG Pharmaceutical Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
CMG Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, CMG Pharmaceutical Co. Ltd's market cap moved from $183.09 Million to $ 107.20 Million, with a yearly change of -6.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩107.20 Million | -42.41% |
| 2025 | ₩186.15 Million | +5.09% |
| 2024 | ₩177.14 Million | -26.64% |
| 2023 | ₩241.46 Million | +12.09% |
| 2022 | ₩215.41 Million | -43.94% |
| 2021 | ₩384.23 Million | -33.65% |
| 2020 | ₩579.10 Million | +36.00% |
| 2019 | ₩425.81 Million | +7.73% |
| 2018 | ₩395.26 Million | -32.13% |
| 2017 | ₩582.39 Million | +96.23% |
| 2016 | ₩296.79 Million | +62.11% |
| 2015 | ₩183.09 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of CMG Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $107.20 Million USD |
| MoneyControl | $107.20 Million USD |
| MarketWatch | $107.20 Million USD |
| marketcap.company | $107.20 Million USD |
| Reuters | $107.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more